(EMAILWIRE.COM, August 12, 2021 ) The Key Growth Elements in Detailed?

The demand for transplant diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the increasing number of transplant procedures, and technological advancements in the field of transplant diagnostics.

Worldwide Growth Opportunities in Terms of Revenue:

The Transplant Diagnostics Market is expected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2019, at a CAGR of 7.2%.

The molecular assays segment is expected to witness the highest growth during the forecast period.

On the basis of technology, the transplant diagnostics market is segmented into molecular assay and non-molecular assay technology. The molecular assay technology segment is expected to register the highest CAGR during the forecast period. Factors such as its varied applications in patient profiling, rising public-private investments to support product development, and increasing clinical evidence of its efficacy are driving the growth of this segment.

The solid organ transplantation segment accounted for the largest share of this market in 2019.

On the basis of transplant type, the transplant diagnostics market is categorized into solid organ, stem cell, and soft tissue transplantation. Solid organ transplantation accounted for the largest share of the diagnostics market in 2019. Supportive government regulations to increase organ donations across major healthcare markets, the rising number of chronic diseases/disorders leading to transplantation, and ongoing technological advancements in the field of transplant diagnostics are the key factors supporting the growth of the market for solid organ transplantation.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=2531061

Regional Growth, Development and Demand Analysis:

North America accounted for the largest share of the transplant diagnostics market in 2019, followed by Europe. This can primarily be attributed to the continuous commercialization of innovative transplant diagnostic products coupled with ongoing advancements in the field of genomics and proteomics, recent discovery genetic biomarkers & their clinical role in immunoassay testing, and the increasing prevalence of chronic and communicable diseases.

Major Key Players Mentioned in the research report are:

Some of the prominent players in the transplant diagnostics market are Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), and bioMérieux S.A. (France). Others are Immucor, Inc. (US), Illumina, Inc. (US), Luminex Corporation (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), and GenDx (Netherlands).

Bio-Rad Laboratories, Inc. is the leading player in the global transplant diagnostics market. The company has a broad range of automated instruments for antibody screening and analysis, semi-automated systems for serological assays, standalone systems & reagents for molecular and non-molecular assay procedures, including transplant diagnostic products. The company has a keen focus on leveraging its core technologies by introducing product line extensions as well as new product offerings. GE Healthcare also seeks strategic partners to develop products. The company tries to evaluate new, emerging, and complementary technologies to identify new product opportunities.

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=2531061

Recent Developments:

- In August 2019, Care Dx (US) acquired XynManagement (US) to simplify transplant quality tracking and waitlist management.

- In March 2019, Hologic established a learning and experience center in Zaventem (Belgium) to create awareness among customers, healthcare professionals, and employees across Europe, the Middle East, and Africa about the benefits of diagnostic products, including transplant diagnostic products.